{"cdcTestId":"2021-0009","testcaseName":"Dose #1 is AstraZeneca Dose #2 is Pfizer Covid-19 Vaccine ","vaccineGroup":"COVID-19","evaluationTestType":"All Valid: Forecast Test","forecastTestType":"Recommended based on interval","assessmentDate":"2022-03-08T00:00:00","patient":{"dob":"1997-09-13T00:00:00","gender":"F"},"evaluation":{"seriesStatus":"Not complete","administeredDoses":[{"dateAdministered":"2022-02-08T00:00:00","vaccineName":"AstraZeneca COVID-19 Vaccine (Non-US tradenames include VAXZEVRIA, COVISHIELD)","cvx":"210","mvx":"ASZ","evaluationStatus":"Valid","evaluationReason":null},{"dateAdministered":"2022-03-08T00:00:00","vaccineName":"Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)","cvx":"208","mvx":"PFR","evaluationStatus":"Valid","evaluationReason":null}]},"forecast":{"forecastNum":"3","earliestDate":"2022-08-08T00:00:00","recommendedDate":"2022-08-08T00:00:00","pastDueDate":"0001-01-01T00:00:00"},"doses":[{"dateAdministered":"2022-02-08T00:00:00","vaccineName":"AstraZeneca COVID-19 Vaccine (Non-US tradenames include VAXZEVRIA, COVISHIELD)","cvx":"210","mvx":"ASZ","evaluationStatus":"Valid","evaluationReason":null},{"dateAdministered":"2022-03-08T00:00:00","vaccineName":"Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)","cvx":"208","mvx":"PFR","evaluationStatus":"Valid","evaluationReason":null}],"dateAdded":"2020-10-06T20:00:00","dateUpdated":"2022-09-27T09:39:14.11","generalDescription":"This test case describes when a patient is administered a first dose of  AstraZeneca Covid-19 Vaccine and a second dose as Pfizer that a third dose is recommended.","changedInVersion":"4.27","reasonForChange":"v4.27  Updated test case to a fixed date test case to retain previous booster recommendations before the updated Covid-19 Interim Clinical Guidance (09/02/2022). \nv4.20: Updated test case to align with Interim Clinical Considerations for \u0022People who received Covid-19 vaccine outside of the United States\u0022 by changing the status of dose #1 to \u0022valid\u0022 and by forecasting a third dose."}